I Rhythm Technologies, Inc. IRTC
We take great care to ensure that the data presented and summarized in this overview for iRhythm Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRTC
View all-
Vanguard Group Inc Valley Forge, PA2.95MShares$262 Million0.01% of portfolio
-
Capital Research Global Investors Los Angeles, CA2.5MShares$222 Million0.07% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$217 Million0.01% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.14MShares$191 Million0.38% of portfolio
-
Sands Capital Management, LLC Arlington, VA2.14MShares$191 Million0.73% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A61.35MShares$120 Million0.24% of portfolio
-
Alliancebernstein L.P. New York, NY1.23MShares$110 Million0.05% of portfolio
-
Jpmorgan Chase & CO New York, NY963KShares$85.7 Million0.01% of portfolio
-
Holocene Advisors, LP New York, NY919KShares$81.7 Million0.41% of portfolio
-
Blair William & CO Chicago, IL833KShares$74.1 Million0.31% of portfolio
Latest Institutional Activity in IRTC
Top Purchases
Top Sells
About IRTC
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Transactions at IRTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2024
|
Brice Bobzien Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,401
-5.15%
|
$155,511
$111.14 P/Share
|
|
Mar 04
2024
|
Daniel G. Wilson EVP, Corp Dev Inv Rel |
SELL
Open market or private sale
|
Direct |
2,452
-7.44%
|
$272,172
$111.14 P/Share
|
|
Mar 04
2024
|
Minang Turakhia EVP, CMO & CSO |
SELL
Open market or private sale
|
Direct |
943
-3.19%
|
$104,673
$111.14 P/Share
|
|
Mar 04
2024
|
Patrick Michael Murphy CBO and CLO |
SELL
Open market or private sale
|
Direct |
1,525
-3.11%
|
$169,275
$111.14 P/Share
|
|
Mar 04
2024
|
Quentin S. Blackford President and CEO |
SELL
Open market or private sale
|
Direct |
4,221
-2.34%
|
$468,531
$111.14 P/Share
|
|
Mar 04
2024
|
Chad Patterson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,077
-2.63%
|
$119,547
$111.14 P/Share
|
|
Mar 04
2024
|
Mark J. Day Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
3,248
-5.04%
|
$360,528
$111.14 P/Share
|
|
Mar 04
2024
|
Sumi Shrishrimal EVP, Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
723
-2.87%
|
$80,253
$111.14 P/Share
|
|
Feb 29
2024
|
Daniel G. Wilson EVP, Corp Dev Inv Rel |
SELL
Open market or private sale
|
Direct |
1,261
-3.68%
|
$152,581
$121.96 P/Share
|
|
Feb 29
2024
|
Mark J. Day Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,475
-2.24%
|
$178,475
$121.96 P/Share
|
|
Feb 29
2024
|
Quentin S. Blackford President and CEO |
SELL
Open market or private sale
|
Direct |
24,701
-12.07%
|
$2,988,821
$121.96 P/Share
|
|
Feb 29
2024
|
Patrick Michael Murphy CBO and CLO |
SELL
Open market or private sale
|
Direct |
7,615
-13.46%
|
$921,415
$121.96 P/Share
|
|
Feb 28
2024
|
Chad Patterson Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,742
+20.78%
|
-
|
|
Feb 28
2024
|
Marc W. Rosenbaum Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,007
+25.72%
|
-
|
|
Feb 28
2024
|
Brice Bobzien Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,593
+24.01%
|
-
|
|
Feb 28
2024
|
Mervin Smith EVP Strategic Business Ops |
BUY
Grant, award, or other acquisition
|
Direct |
5,371
+32.71%
|
-
|
|
Feb 28
2024
|
Daniel G. Wilson EVP, Corp Dev Inv Rel |
BUY
Grant, award, or other acquisition
|
Direct |
5,371
+13.56%
|
-
|
|
Feb 28
2024
|
Sumi Shrishrimal EVP, Chief Risk Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,445
+20.4%
|
-
|
|
Feb 28
2024
|
Minang Turakhia EVP, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
9,883
+25.03%
|
-
|
|
Feb 28
2024
|
Mark J. Day Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,734
+10.51%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 179K shares |
|---|---|
| Exercise of conversion of derivative security | 486 shares |
| Open market or private sale | 66.4K shares |
|---|---|
| Sale (or disposition) back to the issuer | 509 shares |